Comparative effectiveness research has become a pivotal term in Washington these days, particularly after the federal government passed the American Recovery and Reinvestment Act of 2009, which authorized $1.1 billion for comparative effectiveness research. Now an analysis of findings from six focus groups commissioned by the Medicare Payment Advisory Commission, or MedPAC, finds that although physicians think comparative effectiveness research studies are a good idea, their support for such studies depends on a number of factors.